https://mindmedicinelaw.com/briefing/dmt-harmine-formulation-reduces-negative-emotions-in-trials-20260714-21974The Psychedelic Journalen2026-07-14T15:07:09.599688+00:00DMT-Harmine Formulation Reduces Negative Emotions in TrialsDMT, harmine, negative emotions, psychedelic research, clinical trials, ayahuasca, self-referential processing, psychiatric disorders, emotional modulation, mental health treatmenthttps://mindmedicinelaw.com/briefing/fda-hearing-on-psychedelic-therapeutics-implications-for-policy-20260714-21889The Psychedelic Journalen2026-07-14T15:07:01.030844+00:00FDA Hearing on Psychedelic Therapeutics: Implications for PolicyFDA hearing, psychedelic therapeutics, regulatory changes, clinical trials, mental health treatment, therapeutic use of psychedelics, policy implications, psychedelic drugs, public health, drug schedulinghttps://mindmedicinelaw.com/briefing/federal-rfi-on-safe-psychedelic-therapy-models-in-clinics-20260714-21898The Psychedelic Journalen2026-07-14T15:06:51.886951+00:00Federal RFI on Safe Psychedelic Therapy Models in Clinicspsychedelic therapies, FDA approval, mental health treatment, clinical settings, stakeholder feedback, Executive Order 14401, ambulatory clinics, training models, patient safety, regulatory frameworkshttps://mindmedicinelaw.com/briefing/fda-finalizes-guidance-on-psychedelic-clinical-trials-20260714-21897The Psychedelic Journalen2026-07-14T15:06:42.505224+00:00FDA Finalizes Guidance on Psychedelic Clinical TrialsFDA guidance, psychedelic clinical trials, drug development, psychedelic therapies, regulatory framework, clinical research, mental health treatment, safety monitoring, therapeutic potential, psychiatric disordershttps://mindmedicinelaw.com/briefing/generative-art-in-depression-therapy-ethics-and-efficacy-20260713-21975The Psychedelic Journalen2026-07-14T15:07:27.232567+00:00Generative Art in Depression Therapy: Ethics and Efficacygenerative art, depression therapy, digital technology, psychological intervention, ethical challenges, interactive art, emotional mapping, neuro-regulation, sensory overload, virtual escapismhttps://mindmedicinelaw.com/briefing/immune-inflammatory-mechanisms-in-depression-and-metabolic-syndrome-20260713-21984The Psychedelic Journalen2026-07-14T15:07:17.986600+00:00Immune-Inflammatory Mechanisms in Depression and Metabolic Syndromeimmune-inflammatory mechanisms, major depressive disorder, metabolic syndrome, precision therapies, multi-omics studies, chronic low-grade inflammation, immune signaling pathways, personalized management, anti-inflammatory interventions, translational researchhttps://mindmedicinelaw.com/briefing/fda-guidance-streamlines-psychedelic-drug-development-20260713-21888The Psychedelic Journalen2026-07-13T22:04:06.027538+00:00FDA Guidance Streamlines Psychedelic Drug DevelopmentFDA guidance, psychedelic drug development, AtaiBeckley, regulatory uncertainty, psychedelic therapies, clinical trials, mental health, investment in psychedelics, drug safety, therapeutic efficacyhttps://mindmedicinelaw.com/briefing/fda-s-proposed-changes-to-drug-registration-impact-on-psychedelics-20260713-21561The Psychedelic Journalen2026-07-13T15:04:20.822358+00:00FDA's Proposed Changes to Drug Registration: Impact on PsychedelicsFDA, drug registration, psychedelic manufacturing, distributed manufacturing, foreign establishments, regulatory compliance, PREVENT Pandemics Act, market entry, psychedelic industry, drug listing requirementshttps://mindmedicinelaw.com/briefing/ect-study-glutathione-homocysteine-not-linked-to-depression-outcome-20260711-21642The Psychedelic Journalen2026-07-13T15:04:59.440795+00:00ECT Study: Glutathione, Homocysteine Not Linked to Depression Outcomeelectroconvulsive therapy, glutathione, homocysteine, treatment-resistant depression, biomarkers, oxidative stress, bipolar disorder, unipolar disorderhttps://mindmedicinelaw.com/briefing/epigenetic-impact-of-ketamine-mdma-on-brain-health-20260711-21597The Psychedelic Journalen2026-07-13T15:04:09.880966+00:00Epigenetic Impact of Ketamine & MDMA on Brain Healthketamine, MDMA, epigenetic changes, neuroplasticity, neuroimmune regulation, psychiatric health, clinical trials, psychoplastogens, DNA methylation, therapeutic strategieshttps://mindmedicinelaw.com/briefing/u-s-bill-aims-to-enhance-psychedelic-treatment-for-veterans-20260711-21634The Psychedelic Journalen2026-07-13T15:03:58.651623+00:00U.S. Bill Aims to Enhance Psychedelic Treatment for Veteranspsychedelic treatment, veterans, PTSD, psilocybin, legislation, clinical trials, mental health, policy, research, Department of Defensehttps://mindmedicinelaw.com/briefing/cytokine-synergy-in-cns-inflammation-implications-for-ms-20260710-21656The Psychedelic Journalen2026-07-13T22:04:15.537292+00:00Cytokine Synergy in CNS Inflammation: Implications for MScytokine synergy, macrophage polarization, Multiple Sclerosis, neuroinflammation, MS treatment, cytokine interactions, CNS inflammation, therapeutic strategies, macrophage-directed therapies, GM-CSFhttps://mindmedicinelaw.com/briefing/personality-shifts-in-german-students-post-psychedelic-use-20260710-21098The Psychedelic Journalen2026-07-12T22:04:04.010317+00:00Personality Shifts in German Students Post-Psychedelic Usepsychedelic research, personality changes, German students, Openness, Conscientiousness, non-clinical settings, Big Five Inventory, Berlin college students, psychedelic use, neurosciencehttps://mindmedicinelaw.com/briefing/anesthetic-agents-influence-ect-seizure-duration-and-cognition-20260710-21145The Psychedelic Journalen2026-07-12T22:03:56.264639+00:00Anesthetic Agents Influence ECT Seizure Duration and Cognitionelectroconvulsive therapy, anesthetic agents, seizure duration, cognitive recovery, etomidate, ketamine, propofol, randomized controlled trials, mental health treatment, evidence-based guidelineshttps://mindmedicinelaw.com/briefing/future-drug-targets-in-depression-treatment-emerging-therapies-20260710-21146The Psychedelic Journalen2026-07-12T22:03:48.366919+00:00Future Drug Targets in Depression Treatment: Emerging Therapiesdepression treatment, NMDA receptor modulators, pharmacogenomics, personalized medicine, rapid-acting antidepressants, glutamatergic dysfunction, neuroinflammation, brain-derived neurotrophic factor, artificial intelligence in drug discovery, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/digital-technologies-and-altered-states-a-new-frontier-20260710-21097The Psychedelic Journalen2026-07-12T22:03:41.771199+00:00Digital Technologies and Altered States: A New Frontierdigital technologies, altered states of consciousness, virtual reality, biofeedback, artificial intelligence, digital therapeutics, psychophysiological effects, clinical applications, market opportunities, mental healthhttps://mindmedicinelaw.com/briefing/spontaneous-recovery-in-fear-conditioning-implications-for-ptsd-20260710-21276The Psychedelic Journalen2026-07-12T22:03:32.055514+00:00Spontaneous Recovery in Fear Conditioning: Implications for PTSDspontaneous recovery, fear conditioning, PTSD treatment, anxiety relapse, pharmacological interventions, non-pharmacological methods, exposure therapy, clinical trials, neuroscience research, mental health policyhttps://mindmedicinelaw.com/briefing/neurotrophin-system-biomarkers-in-psychiatric-treatment-20260709-21153The Psychedelic Journalen2026-07-13T22:04:55.821728+00:00Neurotrophin System Biomarkers in Psychiatric Treatmentneurotrophin system, psychiatric disorders, biomarkers, clinical trials, therapeutic strategies, mental healthhttps://mindmedicinelaw.com/briefing/novel-morpholine-coumarin-derivatives-a-new-path-in-depression-treatment-20260709-21147The Psychedelic Journalen2026-07-13T22:04:47.323078+00:00Novel Morpholine–Coumarin Derivatives: A New Path in Depression Treatmentcompound 14d, IDO1/TDO inhibitors, depression treatment, kynurenine pathway, neuroinflammation, clinical trials, morpholine–coumarin derivatives, inflammation-associated depression, preclinical researchhttps://mindmedicinelaw.com/briefing/cav2-2-knockout-mice-exploring-behavioral-changes-20260709-21151The Psychedelic Journalen2026-07-13T22:04:35.960513+00:00CaV2.2-Knockout Mice: Exploring Behavioral ChangesCaV2.2-knockout mice, behavioral changes, calcium channels, neurodevelopment, pain signaling, neurological disorders, synaptic function, hyperactivity, exploratory behavior, seizureshttps://mindmedicinelaw.com/briefing/psychedelics-impact-on-thalamocortical-system-implications-20260709-21886The Psychedelic Journalen2026-07-13T22:04:24.907542+00:00Psychedelics' Impact on Thalamocortical System: Implicationspsychedelics, thalamocortical system, serotonin receptors, clinical trials, neural mechanisms, therapeutic applications, mental health, sensory perception, neuroscience, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/sex-specific-psilocybin-effects-in-stress-research-new-insights-20260709-21605The Psychedelic Journalen2026-07-13T15:04:45.177589+00:00Sex-Specific Psilocybin Effects in Stress Research: New Insightspsilocybin research, sex-specific effects, developmental stress, mental health disorders, psychedelic treatments, neuroscience, clinical trials, translational validity, behavioral phenotyping, personalized medicinehttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-treating-addiction-and-depression-potential-and-risks-20260709-21651The Psychedelic Journalen2026-07-13T15:04:32.798994+00:00Ketamine's Role in Treating Addiction and Depression: Potential and Risksketamine, addiction treatment, treatment-resistant depression, neuroplastic effects, substance use disorders, clinical trials, psychotherapy integration, NMDA receptor antagonism, drug misuse risk, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/digital-tool-enhances-alzheimer-s-therapy-eligibility-assessment-20260709-21317The Psychedelic Journalen2026-07-12T22:04:12.770878+00:00Digital Tool Enhances Alzheimer's Therapy Eligibility Assessmentdigital cognitive assessment, MMSE scores, Alzheimer's therapy, health disparities, machine learning, Bio-Hermes-001 study, DCR tool, healthcare policy, digital triage, data privacy